drugset / Trial / NCT00619476

A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

NCT00619476

Phase 2 Completed 376 enrolled XenoPort, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).

Timeline

Start
2008-02
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject gabapentin enacarbil Small molecule 1200 mg
Subject gabapentin enacarbil Small molecule 2400 mg
Subject gabapentin enacarbil Small molecule 3600 mg